Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01333098 · ClinicalTrials.gov registry record · Phase 1
Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
A Phase 1 study of Anxiety Disorders, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01333098: Completed Phase 1 study of Anxiety Disorders, sponsored by Washington University School of Medicine.
NCT01333098 is a Phase 1 study of Anxiety Disorders that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 1,140-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01333098, a Phase 1 study of Anxiety Disorders, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and disabling in older adults. One particularly impairing aspect of late-life anxiety disorders is cognitive impairment: impairments in memory and executive function cause disability, impede treatment response to psychotherapy, may lead to dementia, and are not corrected by standard anti-anxiety treatments. This pilot study will test the glucocorticoid antagonist, mifepristone, for cognitive impairment in late-life anxiety disorders. Mifepristone blocks the effects of elevated cortisol levels on glucocorticoid receptors in the brain; it has been studied preliminarily in various neuropsychiatric disorders, such as psychotic depression and bipolar disorder, with well-documented safety and tolerability.
Primary Outcome
number of participants with dose-limiting side effects
Conditions Studied
Interventions
- DRUG Mifepristone
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
What the finished NCT01333098 record still lists
NCT01333098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,140-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention - of which Mifepristone is the first listed.
NCT01333098 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01333098 about?
NCT01333098 is a clinical study titled "Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders". This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and disabling in older adults. One particularly impairing aspect of late-life anxiety disorders is cognitive impairmen...
What is the current status of trial NCT01333098?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-09. Estimated completion is 2013-04.
What conditions does trial NCT01333098 study?
This clinical trial studies the following conditions: Anxiety Disorders.
What interventions are being tested in trial NCT01333098?
The interventions under investigation include: Mifepristone (DRUG).
Who is sponsoring clinical trial NCT01333098?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01333098 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01333098's enrollment target sits among peer trials
15 82nd of 84 higher than 2 of 84 other Anxiety Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindfulness-based Stress Reduction and Cognitive Function in Stress and Aging
COMPLETED · Phase 1
-
Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders
COMPLETED · Phase 1
-
Treatment for Specific Phobias in Children
COMPLETED · Phase 1
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia